HomeCompareLZAGF vs JEPQ

LZAGF vs JEPQ: Dividend Comparison 2026

LZAGF yields 1.10% · JEPQ yields 11.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JEPQ wins by $268.00 in total portfolio value
10 years
LZAGF
LZAGF
● Live price
1.10%
Share price
$650.29
Annual div
$7.14
5Y div CAGR
45.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.5K
Annual income
$8,733.09
Full LZAGF calculator →
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.10%
Share price
$55.52
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.8K
Annual income
$2,152.59
Full JEPQ calculator →

Portfolio growth — LZAGF vs JEPQ

📍 JEPQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLZAGFJEPQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LZAGF + JEPQ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LZAGF pays
JEPQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LZAGF
Annual income on $10K today (after 15% tax)
$93.36/yr
After 10yr DRIP, annual income (after tax)
$7,423.13/yr
JEPQ
Annual income on $10K today (after 15% tax)
$943.83/yr
After 10yr DRIP, annual income (after tax)
$1,829.70/yr
At 15% tax rate, LZAGF beats the other by $5,593.43/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LZAGF + JEPQ for your $10,000?

LZAGF: 50%JEPQ: 50%
100% JEPQ50/50100% LZAGF
Portfolio after 10yr
$44.7K
Annual income
$5,442.84/yr
Blended yield
12.19%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on LZAGF right now

LZAGF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
4.3
Piotroski
7/9
JEPQ
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LZAGF buys
0
JEPQ buys
0
No recent congressional trades found for LZAGF or JEPQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLZAGFJEPQ
Forward yield1.10%11.10%
Annual dividend / share$7.14$6.16
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR45.9%0%
Portfolio after 10y$44.5K$44.8K
Annual income after 10y$8,733.09$2,152.59
Total dividends collected$22.1K$16.3K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: LZAGF vs JEPQ ($10,000, DRIP)

YearLZAGF PortfolioLZAGF Income/yrJEPQ PortfolioJEPQ Income/yrGap
1← crossover$10,860$160.25$11,930$1,110.39$1.1KJEPQ
2$11,858$237.31$14,133$1,224.34$2.3KJEPQ
3$13,041$353.30$16,632$1,340.46$3.6KJEPQ
4$14,484$529.82$19,454$1,457.97$5.0KJEPQ
5$16,300$802.36$22,626$1,576.08$6.3KJEPQ
6$18,672$1,231.24$26,175$1,694.09$7.5KJEPQ
7$21,903$1,923.20$30,133$1,811.32$8.2KJEPQ
8$26,512$3,076.05$34,531$1,927.17$8.0KJEPQ
9$33,445$5,077.02$39,403$2,041.08$6.0KJEPQ
10$44,519$8,733.09$44,787$2,152.59$268.00JEPQ

LZAGF vs JEPQ: Complete Analysis 2026

LZAGFStock

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia and New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was founded in 1897 and is headquartered in Basel, Switzerland.

Full LZAGF Calculator →

JEPQETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →
📬

Get this LZAGF vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LZAGF vs SCHDLZAGF vs JEPILZAGF vs OLZAGF vs KOLZAGF vs MAINLZAGF vs XYLDLZAGF vs QYLDLZAGF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.